Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review
The FASEB Journal · 31.10.2025 · 39 (20)
DOI: 10.1096/fj.202502118r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 24.10.2025. Verfasst von Bantayehu Addis Tegegne und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia. Hauptthemen laut MEDLINE: Probiotics, Prebiotics, Synbiotics, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The gut microbiome plays a pivotal role in cancer development, progression, and treatment response, driving interest in microbiome‐based interventions. This review examines probiotics, prebiotics, synbiotics, and postbiotics (PPSPs) as precision tools in oncology, highlighting their mechanisms, clinical applications, and challenges. Gut microbiota influence cancer through immune modulation, metabolic regulation, and inflammatory control, while also shaping chemotherapy pharmacokinetics and immunotherapy efficacy. PPSPs demonstrate antitumor effects via: (1) immune activation, (2) intestinal barrier reinforcement, (3) pathogen suppression, and (4) carcinogen neutralization. Clinically, probiotics/postbiotics reduce chemotherapy‐induced mucositis and enhance checkpoint inhibitor responses, while synbiotics/prebiotics selectively nourish beneficial microbes. Despite promise, hurdles like strain‐specific variability, dosing optimization, and individual microbiome differences hinder translation. By integrating preclinical and clinical data, this review underscores PPSPs' potential to bridge gut ecology with antitumor immunity, advancing precision oncology. Future priorities include large‐scale trials, standardized protocols, and mechanistic insights into host‐microbiome‐cancer crosstalk. Personalized microbiota therapies, engineered consortia, and combination regimens represent promising frontiers. With robust evidence, PPSPs may emerge as essential adjuvants, improving outcomes while minimizing toxicity in cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia.
- Department of Medical Laboratory Science, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia.
- Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
ORCID-Profile: Bantayehu Addis Tegegne
Zitieren
APA
Tegegne, B. A., Abebaw, D., Teffera, Z. H., Fenta, A., Belew, H., Belayneh, M., Jemal, M., Getinet, M., Baylie, T., Tamene, F. B., Belay, W. Y., Wondim, S. A., & Zeleke, T. K. (2025). Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review. The FASEB Journal, 39(20). https://doi.org/10.1096/fj.202502118r
Vancouver
Tegegne BA, Abebaw D, Teffera ZH, Fenta A, Belew H, Belayneh M, et al. Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review. The FASEB Journal. 2025;39(20). doi:10.1096/fj.202502118r
BibTeX
@article{Tegegne2025,
author = {Tegegne, Bantayehu Addis and Abebaw, Desalegn and Teffera, Zigale Hibstu and Fenta, Abebe and Belew, Habtamu and Belayneh, Mekuriaw and Jemal, Mohammed and Getinet, Mamaru and Baylie, Temesgen and Tamene, Fasil Bayafers and Belay, Wubetu Yihunie and Wondim, Samual Agegnew and Zeleke, Tirsit Ketsela},
title = {Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {20},
doi = {10.1096/fj.202502118r}
}
EUVIMED